Understanding immune responses to factor VIII in hemophilia A
Defining the Innate Immune Cell Profile of Factor VIII Immunity
This study is looking at how the immune system responds to a key protein used in treating hemophilia A, with the goal of finding ways to stop the body from creating antibodies that make the treatment less effective, so patients can have better outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11062131 on NIH RePORTER |
What this research studies
This research investigates how the immune system reacts to factor VIII, a crucial protein for blood clotting, in patients with hemophilia A. It aims to identify the immune cells involved and the mechanisms that lead to the development of inhibitors, which are antibodies that neutralize the effectiveness of factor VIII treatments. By understanding these processes, the research seeks to develop new therapies that can prevent these inhibitors from forming and improve treatment outcomes for patients. The approach includes analyzing immune cell profiles and early immunologic events related to factor VIII immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with hemophilia A who have developed inhibitors against factor VIII or are at risk of developing them.
Not a fit: Patients without hemophilia A or those who do not have issues with factor VIII treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hemophilia A, reducing complications and improving the quality of life for patients.
How similar studies have performed: Previous research has shown promise in understanding immune responses in hemophilia, but this specific approach to defining immune cell profiles and developing targeted therapies is relatively novel.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Batsuli, Glaivy — Stanford University
- Study coordinator: Batsuli, Glaivy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.